Dr. Reddy's CEO Erez Israeli Notices Sale of 460,726 ADRs (~$6.5M)
RDY sits 24% above its 52-week low of $11.36 on light trading volume (0.2× avg).
Summary
Dr. Reddy's CEO Erez Israeli filed notice to sell 460,726 ADRs worth roughly $6.54M, acquired via stock options, with an approximate sale date of October 29, 2026.
Key Events · Ownership and Investor Activity · RDY
-
CEO Files Notice to Sell 460,726 ADRs
Erez Israeli, CEO, noticed intent to sell 460,726 sponsored ADRs with an approximate market value of $6,542,310 and an approximate sale date of 10/29/2026.
-
Shares Sourced From Stock Options
The ADRs were acquired 10/28/2025 through stock options, so the sale converts existing equity compensation into cash rather than reducing a direct open-market stake.
-
No Prior Sales in Past 3 Months
The filing reports nothing sold in the past three months, making this the first disclosed sale in the recent window.
-
Follows Weak Q2 FY2026 Results
The notice comes after the 2026-10-23 6-K reporting Q2 FY2026 profit down 36% year over year to Rs. 9,134 million on a 29% drop in North America generics revenue.
Analysis · RDY · Life Sciences
The CEO has filed a Form 144 to sell 460,726 sponsored ADRs worth about $6.54M, shares acquired through stock options. This is a notice of intent, not a completed sale, and it marks the first insider sale disclosed in the recent timeline. Against a company of this scale the size is modest, but a CEO selling draws closer scrutiny than a routine holder, and the notice lands just ten days after Q2 FY2026 results showed profit down 36% and North America generics revenue down 29%.
How filings like this one have moved
In the 30 days to Nov 2, 2026, 32.7% of the 1910 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RDY was trading at $14.10 on NYSE in the Life Sciences sector, with a market capitalization of approximately $11.9B. The 52-week trading range was $11.36 to $15.67. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.